939 related articles for article (PubMed ID: 29890986)
1. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients.
Hu H; Yao X; Xie X; Wu X; Zheng C; Xia W; Ma S
World J Urol; 2017 Feb; 35(2):261-270. PubMed ID: 27255479
[TBL] [Abstract][Full Text] [Related]
3. Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.
Wang Z; Liu N; Gan W; Li X; Zhang G; Li D; Guo H
J Int Med Res; 2017 Aug; 45(4):1287-1296. PubMed ID: 28587544
[TBL] [Abstract][Full Text] [Related]
4. The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients.
Guo S; He X; Chen Q; Yang G; Yao K; Dong P; Ye Y; Chen D; Zhang Z; Qin Z; Liu Z; Xue Y; Zhang M; Liu R; Zhou F; Han H
BMC Cancer; 2017 Mar; 17(1):171. PubMed ID: 28264659
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated with Survival From Xp11.2 Translocation Renal Cell Carcinoma Diagnosis-A Systematic Review and Pooled Analysis.
Wu Y; Chen S; Zhang M; Liu K; Jing J; Pan K; Zhang L; Xu B; Lu X; Chen M
Pathol Oncol Res; 2021; 27():610360. PubMed ID: 34257577
[No Abstract] [Full Text] [Related]
6. Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.
Liu N; Wang Z; Gan W; Xiong L; Miao B; Chen X; Guo H; Li D
PLoS One; 2016; 11(11):e0166897. PubMed ID: 27893792
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions-single-center study].
Ma WL; Liu N; Zhuang WY; Li XG; Zhang GT; Gan WD; Guo HQ
Zhonghua Yi Xue Za Zhi; 2018 Oct; 98(38):3068-3073. PubMed ID: 30392265
[No Abstract] [Full Text] [Related]
8. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
[TBL] [Abstract][Full Text] [Related]
9. Xp11.2 Translocation Renal Cell Carcinoma: Clinical Characteristics and Potential Prognostic Predictors.
Dong J; Xu W; Ji Z; Pan B
Dis Markers; 2021; 2021():5647933. PubMed ID: 34512814
[TBL] [Abstract][Full Text] [Related]
10. The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes.
Albisinni S; Pretot D; Al Hajj Obeid W; Aoun F; Quackels T; Peltier A; Roumeguère T
Prog Urol; 2019; 29(8-9):423-431. PubMed ID: 31196826
[TBL] [Abstract][Full Text] [Related]
11. The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis.
Al-Maghrabi J; Mufti S; Gomaa W
Pol J Pathol; 2018; 69(4):376-383. PubMed ID: 30786687
[TBL] [Abstract][Full Text] [Related]
12. Estrogen associates with female predominance in Xp11.2 translocation renal cell carcinoma.
Lu Y; Zhu Y; Ma W; Liu N; Dong X; Shi Q; Yu F; Guo H; Li D; Gan W
Sci Rep; 2023 Apr; 13(1):6141. PubMed ID: 37061606
[TBL] [Abstract][Full Text] [Related]
13. Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
Hayes M; Peckova K; Martinek P; Hora M; Kalusova K; Straka L; Daum O; Kokoskova B; Rotterova P; Pivovarčikova K; Branzovsky J; Dubova M; Vesela P; Michal M; Hes O
Virchows Arch; 2015 Mar; 466(3):313-22. PubMed ID: 25544614
[TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis.
Klatte T; Streubel B; Wrba F; Remzi M; Krammer B; de Martino M; Waldert M; Marberger M; Susani M; Haitel A
Am J Clin Pathol; 2012 May; 137(5):761-8. PubMed ID: 22523215
[TBL] [Abstract][Full Text] [Related]
15. A Novel Inflammation-Based Prognostic Score, the C-Reactive Protein/Albumin Ratio Predicts the Prognosis of Patients with Operable Esophageal Squamous Cell Carcinoma.
Xu XL; Yu HQ; Hu W; Song Q; Mao WM
PLoS One; 2015; 10(9):e0138657. PubMed ID: 26390126
[TBL] [Abstract][Full Text] [Related]
16. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
[TBL] [Abstract][Full Text] [Related]
17. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
[TBL] [Abstract][Full Text] [Related]
18. Pseudocapsule of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: a clue for tumor enucleation?
Cheng X; He J; Gan W; Fan X; Yang J; Zhu B; Guo H
Int J Clin Exp Pathol; 2015; 8(5):5403-10. PubMed ID: 26191243
[TBL] [Abstract][Full Text] [Related]
19. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
20. Surgical treatment for Xp11.2 translocation renal cell carcinoma with venous thrombus: A STROBE-compliant study.
Ge L; Tian X; Ma J; Zhao G; Song Y; Zhang S; Ma L
Medicine (Baltimore); 2019 Sep; 98(37):e17172. PubMed ID: 31517871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
